#7 Biogen Idec
Ticker: BIIB
YTD performance: 41%
Market cap: $22.8 billion

Biogen Idec (BIIB), a maker of specialized treatments for neurological diseases like multiple sclerosis, benefited from two positive developments in its drug pipeline this year.

In April, the company announced positive results from a Phase 3 clinical trial for a new MS treatment called BG-12. Phase 3 trials are often the last step in a drug's development before it heads to market.

Later that month, the Food and Drug Administration approved the drug Rituxan, which Biogen co-developed with Roche's (RHBBY) Genentech, for use in treating two extremely rare diseases -- Wegener's Granulomatosis and Microscopic Polyangiitis.The combination of those two events sent shares of Biogen up more than 30% in April alone.




All data current as of June 17, 2011.
Last updated June 29 2011: 7:39 AM ET
Join the Conversation

The market has had its struggles in the first half of the year, but these 10 stocks are really making a stink. From RadioShack to AIG, here are the biggest losers so far in 2011. More

The Federal Reserve's $600 billion bond buying stimulus is winding down, and experts say stocks don't need anything more. More

Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.